S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
"We will NEVER sell out to China!" (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"We will NEVER sell out to China!" (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:QURE

uniQure - QURE Price Target & Analyst Ratings

$26.46
+0.77 (+3.00%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$25.32
$26.66
50-Day Range
$16.98
$27.32
52-Week Range
$12.52
$30.41
Volume
881,707 shs
Average Volume
833,113 shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.71

uniQure Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$48.71
84.11% Upside
High Prediction$65.00
Average Prediction$48.71
Low Prediction$24.00
TypeCurrent
12/1/21 to 12/1/22
1 Month Ago
11/1/21 to 11/1/22
3 Months Ago
9/2/21 to 9/2/22
1 Year Ago
12/1/20 to 12/1/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
11 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$48.71$45.86$48.38$60.15
Predicted Upside84.11% Upside162.00% Upside153.85% Upside75.49% Upside
Get uniQure Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.


QURE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

QURE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

uniQure Stock vs. The Competition

TypeuniQureMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside84.11% Upside577.24% Upside11.48% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
624
72.14%
Underperform Votes
241
27.86%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/23/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$47.00 ➝ $57.00+127.54%
11/23/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$51.00 ➝ $65.00+182.61%
11/3/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/2/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/9/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$65.00 ➝ $60.00+208.01%
8/9/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$34.00 ➝ $24.00+28.76%
5/5/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$66.00 ➝ $37.00+142.78%
3/17/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$40.00+151.73%
12/16/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeStrong-Buy ➝ Outperform$75.00 ➝ $58.00+186.56%
9/14/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
7/27/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$78.00 ➝ $27.46+1.67%
6/14/2021BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$46.00+31.84%
5/19/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$80.00 ➝ $90.00+176.33%
4/1/2021Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$52.00+54.35%
1/7/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$62.00+60.87%
12/22/2020Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Outperform$53.00 ➝ $61.00+58.40%
12/9/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Buy$55.00 ➝ $62.00+30.50%
11/11/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$59.00+34.09%
7/31/2020Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Madhu Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$58.00 ➝ $57.00+44.71%
12/20/2019SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$90.00+29.76%
12/3/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$80.00+25.16%
12/3/2019Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
(Data available from 12/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












QURE Price Target - Frequently Asked Questions

What is uniQure's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for uniQure stock is Moderate Buy based on the current 1 hold rating and 6 buy ratings for QURE. The average twelve-month price prediction for uniQure is $48.71 with a high price target of $65.00 and a low price target of $24.00. Learn more on QURE's analyst rating history.

Do Wall Street analysts like uniQure more than its competitors?

Analysts like uniQure more than other Medical companies. The consensus rating for uniQure is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how QURE compares to other companies.

Do MarketBeat users like uniQure more than its competitors?

MarketBeat users like uniQure more than other Medical companies. 72.14% of MarketBeat users gave uniQure an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Does uniQure's stock price have much upside?

According to analysts, uniQure's stock has a predicted upside of 146.82% based on their 12-month price targets.

What analysts cover uniQure?

uniQure has been rated by Cantor Fitzgerald, The Goldman Sachs Group, Truist Financial, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:QURE) was last updated on 12/1/2022 by MarketBeat.com Staff